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Abstract
Using optimized administration of 13C-labeled glucose, the time course of the
specific activity of glucose was measured directly by in vivo 13C-NMR in the
human brain at 4 Tesla. Subsequent label incorporation was measured at the
C2, C3 and C4 positions of both glutamate and the well-resolved C2, C3 and
C4 resonances of glutamine and at the C2 and C3 positions of aspartate.
GABA was clearly observed for the first time in vivo, suggesting a substantial
GABA turnover in the normal human visual cortex. Likewise, lactate C3
labeled with an estimated active pool size on the order of 0.5 mM. A model of
cerebral glutamate metabolism is proposed which predicts that glutamatergic
action (‘neurotransmission’), pyruvate carboxylase flux, TCA cycle activity,
glucose consumption and exchange across the mitochondrial membrane can
be assessed simultaneously in the human brain.
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Introduction
Glucose is the main substrate used for energy metabo-
lism by the normal human brain. Once transported across
the blood-brain barrier, glucose is readily metabolized [1,
2]. Studies of nervous tissue have shown that label from
glucose accumulates in the intermediates of glycolysis and
of the TCA cycle, as well as in glutamate (Glu), glutamine
(Gln), GABA, lactate (Lac), alanine (Ala) and aspartate
(Asp) [3–6]. The mechanism for label accumulation was
attributed to active exchange reactions between amino
acids and TCA cycle intermediates [7, 8]. The major exci-
tatory neurotansmitter Glu [9] is present in the mammali-
an brain in high concentrations and is dynamically stored
in vesicles [10]. To avoid excitotoxic nerve cell damage,
the extracellular concentration of Glu must be main-
tained very low (F0.004 mM), which is achieved by effi-
cient high-affinity transport primarily into glia.
Experiments have long suggested that cerebral metabo-
lism is compartmentalized. Early radioisotope studies
performed in animal brain between 1950 and 1970 in
which an abnormal product-precusor relationship was
observed between Glu and Gln led to the conclusion that
cerebral metabolism is characterized by at least two com-
partments that differ by the size of the respective Glu
pools [1]. These measurements have been recently ex-
tended using 13C-NMR spectroscopy of brain slices [11],
extracts [5, 12, 13] and cell cultures [14]. Cellular com-
partmentation of metabolism has been further supported
by the glial localization of Gln synthetase (EC 6.3.1.2)
[15], as well as pyruvate carboxylase (EC 6.4.1.1) [16] and
by the observation that acetate uptake and metabolism
takes place predominantly in astrocytes. In addition, glu-
taminase (EC 3.5.1.2) activity has been localized predom-
inantly to the neuronal compartment [17]. Morphological
evidence suggests that most Gln is normally located in
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astrocytes and glia, whereas Glu is located in the neuronal
compartment, most probably in the neuropil [18]. Com-
partmentation of metabolism may also be present at the
level of glycolysis, consistent with a predominantly glial
glycolytic activity and oxidative metabolism being pre-
dominant in neurons, thus providing a further link be-
tween glial energy metabolism and neuronal activation
[2]. In summary, most evidence supports the notion that
the compartmentalized glial-neuronal metabolic relation-
ship is essential to neurotransmission.
Most of the aforementioned evidence on cerebral me-
tabolism has been derived from studies performed either
on cell cultures, brain extracts or on cell preparations. It is
unclear to what extent they reflect the physiologic situa-
tion present in vivo in the human brain, since several
problems may limit the accuracy of these findings: (a) It is
known that vesicles containing Glu are docked at the pre-
synaptic membrane and are ready to release Glu almost
instantaneously, which may happen during the finite time
of any extraction process. (b) Cell cultures, on the other
hand, have the drawback that the culturing process can
influence gene transcription and protein expression and
thereby lead to altered enzyme activities and cells in cul-
ture are removed from the important regulatory signals
contained within the whole animal. Quantitation of rela-
tive activities of metabolic pathways from cell culture
may thus not reflect the in vivo situation accurately.
(c) Brain slices may have a hypoxic core, the neuronal
connections are by design severed and may thus have
altered rates of neuronal-glial metabolic trafficking. Final-
ly, (d) fixation studies combined with immunochemical
assays provide still images of cerebral compartmentation
and do not allow investigation of the dynamic living sys-
tem.
NMR is a powerful method to study tracer uptake in
the in vivo brain [11, 19]. Different approaches and iso-
topes have been used, such as indirect 13C and 15N detec-
tion [20–23]. When using 13C-labeled substrate, direct
13C-NMR detection can be a powerful analytical method
to study complex metabolic interactions in cerebral tissue
in vitro, in situ and in vivo [4, 24–27]. Cerebral TCA cycle
activity [7, 21], mitochondrial exchange [8], malate-
aspartate shuttle [28] and pyruvate carboxylase [5] have
been studied using 13C-NMR. Extensions of these meth-
ods to in vivo brain have been reported by only a few stud-
ies [6, 25]. Although 13C signals can in principle be
observed using heteronuclear correlation spectroscopy by
detecting 13C chemical shift evolution from the attached
1H-, 13C-NMR remains to date the only method that can
reliably quantitate distinct signals from all Glu and Gln
carbon positions noninvasively in a direct manner. Thus
13C-NMR has excellent potential to study neurochemistry
in humans. To date, only one study of cerebral Glu and
Gln metabolism using localized 13C-NMR has been re-
ported in humans [6]. That study also observed in vivo
homonuclear coupling in the glutamate molecule which
was observed despite infusion of singly labeled glucose
because of subsequent metabolism and label scrambling
in the TCA cycle. 13C-NMR has not been easy in vivo
because of the increased chemical shift dispersion and
inherently low sensitivity. The first proton decoupled 13C-
NMR of the human head was reported at 1.5 Tesla [29],
which showed amidst the presence of dominant lipid sig-
nals, glucose and glutamate resonances during 99% glu-
cose infusions. Using higher order shimming and three-
dimensional localization methods, a study quantified lo-
calized glucose signals in the human brain at 2.1 Tesla
using 50% enriched infusions [30]. Most recently, these
studies were extended to the measurement of brain glu-
cose using natural abundance 13C-NMR at 4 Tesla [31].
The time courses of Glu and Gln labeling during 13C glu-
cose infusions reported in Gruetter et al. [6] were modeled
to derive cerebral metabolic rates which provided the first
assessment of cerebral glutamine turnover rates in hu-
mans [7]. The present study extends these observations to
the simultaneous, but separate observation of all CHn, i.e.
proton bound, carbon resonances of Glu and Gln. To
achieve the necessary sensitivity, several limitations of
13C-NMR had to be overcome, namely the low sensitivity,
the demands on localization due to the large chemical
shift displacement error and broadband decoupling.
Some of these achievements have been recently de-
scribed, based on natural abundance detection of many
metabolites [31–33].
It was the purpose of this study to further demonstrate
that in conjunction with 13C-labeled substrate such as
1-13C glucose, most of the technical obstacles to routinely
study human brain (and thus also animal brain) in vivo
with 13C-NMR can be overcome. In addition, we propose
a simplified model describing glial-neuronal metabolism
and test some of its predictions on the in vivo data
obtained from the human brain.
Materials and Methods
A total of 4 subjects were studied after giving informed consent
according to procedures approved by the Institutional Review Board.
On the morning of study, the subject reported to the Center for Mag-
netic Resonance Research in the fasting state. In preparation for the
clamp procedure, an intravenous catheter was placed antegrade in
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each forearm and retrograde into a foot. The extremity into which a
catheter was placed was warmed by preheated pads to arterialize the
venous blood [34]. Somatostatin was infused into one arm vein at a
progressively increasing rate up to 0.16 Ìg/kg/min to suppress endog-
enous pancreatic insulin and glucagon secretion [35]. 30 g of 99%
enriched 1-13C D-glucose (50% weight/volume; Isotech, Miamisburg,
Ohio, USA) was infused into the other arm vein using a bolus infu-
sion over 2–5 min. 70% 1-13C D-glucose was infused thereafter at a
variable rate adjusted to maintain target glycemia above 10 mM.
Alterations in the glucose infusion rate were made based on the plas-
ma glucose concentration measured on a nearby blucose analyzer
(Beckman, Fullerton, Calif., USA) in blood samples taken from the
foot vein every 3–5 min.
All studies used a 4 Tesla magnet with a 125-cm bore, equipped
with a standard clinical body gradient coil and amplifier (Siemens
AS25, Erlangen, Germany). The magnet and gradient system was
interfaced with a spectrometer console (Varian, Palo Alto, Calif.,
USA) using a manufacturer-supplied interface board. Subjects were
positioned supine on the patient bed above the surface coil. After coil
tuning, magnetic resonance imaging was performed to determine
localization for spectroscopy according to anatomical landmarks.
Subjects wore earplugs to minimize gradient noise and were placed
into the coil holder using cushions to minimize head movement.
Shimming of the identified region of interest was performed using
FASTMAP [36], which resulted in water linewidths of 7–9 Hz.
To efficiently separate the proton (169 MHz) and the 13C fre-
quency (42.5 MHz) we used a three coil design where the circular
polarized 1H radiofrequency (RF) field was generated by two distinct
coils driven by a quadrature hybrid. The 13C coil was a single loop
7 cm diameter surface coil. This three coil design was recently
described elsewhere [33]. To ensure further electrical isolation to
enable 1H decoupling during the data acquisition, the cable feeding
the 13C coil was filtered using a low-pass filter and the 1H RF path
was filtered using a 1H bandpass filter. This arrangement ensured
that insertion loss prior to the first amplification stage was at most
0.2 dB [33]. Observation of the FDA guidelines for power absorption
was verified using methods and procedures presented in detail else-
where [32, 33]. RF power for excitation, polarization transfer and
decoupling was carefully calibrated using a small sphere containing
0.5 ml of 13C-labeled formic acid placed at the 13C coil center as
described previously [see 32 and references therein]. These calibra-
tions were used to ensure proper power settings for decoupling as well
as to minimize RF power needed for the experiment.
Localization was performed on the longitudinal proton z-magne-
tization, which was transferred to the 13C magnetization using polari-
zation transfer, PRoton Excited Carbon-13 Image SElected in vivo
Localized spectroscopyY, or PRECISELY [32]. For the current
study, we replaced the 13C part of the pulse sequence using a seg-
mented 0° BIR-4 pulse [37]. Use of this pulse improved stability of
the method in that the signal generated was much less dependent on
spatial RF power precalibrations. Adiabaticity of the pulse sequence
was verified using a cylindrical phantom consisting of 4-13C gluta-
mate placed into a bottle filled with a solution containing natural
abundance equimolar NAA and Cr (10 mM).
Spectra were analyzed using the peak fitting software algorithm
supplied by the spectrometer software. To reduce variability, peak
linewidths of 13C-13C doublets were set to that of the corresponding
center peak and the fitted frequencies of the 13C-13C doublets were
verified to be symmetric to the main resonance.
Preliminary fitting to multiple time courses was done simulta-
neously analogous to a recent report [8], which permitted analysis of
parameter covariance. Metabolite concentrations were assumed con-
stant and the rate constants indicated were fitted. Fitting was based
on coupled differential equations that were derived from the princi-
ple that the rate of label accumulation in a product P is given by
d13P
dt
(t) = ™
i
Vi
(in) 
13Si(t)
Si
– ™
j
Vj
(out) 
13P(t)
P
(1)
where it was assumed that multiple pathways (denoted by the sub-
strates Si and the fluxes Vi
(in)can form the metabolite P and that mul-
tiple reactions can use P as a substrate, with the corresponding flux
denoted by Vj
(out). Note that equation 1 is specific for a given carbon
nucleus in a specific molecule: For instance, ·-ketoglutarate (·-KG)
C4 receives label from acetyl-CoA and thus eventually from pyruvate
C3, whereas ·-KG C3 receives label that previously passed through
·-KG C4. It is beyond the scope of this paper to present the deriva-
tion of the specific differential equations used in the calculations.
Briefly, the following approach was used: (a) metabolic steady state
was assumed, i.e. in equation 1 metabolite concentrations, such as Si
or P, were assumed to be constant in time, as were metabolic rates, V;
(b) all metabolic intermediates of glycolysis and TCA cycle were
assumed to have a small concentration relative to the metabolic rate
such that their effect on the labeling kinetics was ignored in the mod-
eling; (c) lactate was assumed to be in fast exchange with pyruvate
(Pyr) and thus replaced the latter; (d) that exchange of lactate across
the cell membranes was fast such that Lac represents a single kinetic
pool in brain [38].
Results
The sensitivity afforded by the 4 Tesla field and by the
PRECISELY pulse sequence was sufficient to measure
the natural abundance brain glucose signal of the C2-C5
carbons in unlocalized spectra within 12 min and the con-
comitant measurement of the C1 resonance as shown in
figure 1A. Using correction factors determined in a phan-
tom with natural abundance glucose from the peak inten-
sity at 76.6 ppm relative to the C1 position, the in vivo
enrichment of glucose was calculated in the human brain
in two studies 60 min after infusion start. The time course
of plasma glucose and the brain glucose fractional enrich-
ment, estimated from the steady-state value determined
as above and then calculated from the brain 13C signal
divided by the plasma concentration is shown in fig-
ure 1B. The fractional enrichment achieved was highly
reproducible and consistent with the increment of plasma
glucose generated by the bolus method of 13C glucose
administration. The NMR measurement of fractional en-
richment of glucose was assumed to represent fractional
enrichment of brain glucose based on a relatively small
contribution of blood signal (CBV is approximately 5%)
and based on the observation that brain glucose signal
Study 1
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Fig. 1. Direct in vivo measurement of the fractional enrichment
of glucose. A shows the expanded spectral region covering the glucose
resonances and the inositol resonances, acquired from a human head
in 12 min without gradient localization. The peak at 76.6 ppm (ar-
row) is from the C3 and C5 of natural abundance ß-D-glucose. The
time course calculated from the calibrated ratio of 1–13C tissue glu-
cose signal to total plasma glucose is shown in B for two studies, indi-
cating a highly reproducible administration of labeled glucose. The
squares indicate the thus estimated brain glucose fractional enrich-
ment (left scale) and the lines indicate the plasma glucose (right scale)
during these studies. The open squares and dashed line correspond to
subject 1 in table 1 and the solid squares and solid line to subject 2.
Fig. 2. Localized in vivo spectrum of the human occipital lobe.
Shown is a spectrum acquired in 50 min from a 72-ml volume
approximately 60 min after the start of the infusion. The top trace is
an expansion of the bottom trace to highlight the observation of
homonuclear 13C-13C coupling in the glutamate resonances and ten-
tatively in the aspartate resonances. Processing consisted of 2 Hz
Lorentz-to-Gauss resolution enhancement.
closely mimics that of plasma glucose [39], even when
using no other localization means than the RF profile of
the surface coil. Brain glucose enrichment and the con-
comitant increase of plasma glucose above baseline im-
mediately following the 1-13C bolus are tabulated in the
first three columns of table 1. For such a short infusion
time (2–5 min for bolus administration) the increment in
plasma glucose produced with 99% enriched 1-13C glu-
cose allows to estimate the enrichment of plasma glucose,
provided total body glucose consumption can be ne-
glected over such a short time period.
The linewidths of glutamate ranged from 3 to 8 Hz in
the in vivo spectra. A spectrum acquired 60 min after
start of the infusion is shown in figure 2. The bottom
Table 1. Measurement of the increment in plasma glucose (% of
baseline value, measured at t 15–10 min) generated by a bolus injec-
tion of 99% enriched glucose, fractional enrichment measured in the
brain by NMR and the doublet content of total signal intensity in
glutamate; measurements are from the two studies shown in fig-
ure 1B
Plasma
increase
FE by
NMR
C2 C4 C3
64% 69% 22% 18% 34%
Study 2 61% 64% 20% 17% 31%
1A 1B
2
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Fig. 3. Time course of the C4 (A) and C2 (B) amino acid reso-
nances after infusion of 1–13C labeled glucose. In A, the Glu C4 (solid
squares) and Gln C4 (solid diamonds) signal intensities (left scale)
are plotted together with the brain glucose fractional enrichment
(dotted line, right scale). The dotted line indicates the plasma glucose
enrichment (right scale). The solid line and dashed line represent the
best fit to this data using a model of cerebral brain metabolism
(fig. 5). Note the variation in glucose fractional enrichment produced
by resuming the 13C glucose infusion. In B, the time course of the
amino acid C2 resonances is shown from one subject. Note the stabil-
ity of the NAA C2 peak (open circles). The closed diamonds indicate
Glu C2, the open squares denote Gln C2 and the open squares Asp
C2. The tissue fractional enrichment in B is indicated by the dotted
line (right scale).
trace shows the spectral range covered by the CHn reso-
nances of the amino acids. Distinct resonances from Glu
C2-C4, Gln C2-C4 were clearly observed in all studies. In
addition, the Glu resonances contain 13C-13C doublet res-
onances observed as doublets at the C3 and C4 position
and as a downfield peak at the C2 position. The upfield
peak of the Glu C2 13C-13C doublet overlaps partially
with the Gln C2 resonance and generates a detectable
downfield shoulder at the Gln C2 position. The relative
doublet content of each Glu resonance varied in concor-
dance with the slight difference observed in the brain glu-
cose enrichment between the two human studies shown
in table 1. We tentatively observed peaks about the Asp
resonances, consistent with 13C-13C doublets also being
observed in Asp. The relative intensity in Asp C3 was
estimated to be comparable to those observed in Glu C4.
The spectrum in figure 2 shows that the GABA C2 res-
onance was clearly resolved from all Glu C4 peaks. In
addition, an upfield shoulder of the natural abundance
aspartyl NAA peak at 40.4 ppm was tentatively observed,
consistent with the chemical shift of the GABA C4 reso-
nance. Peak intensity of GABA C2 was estimated relative
to Glu and found to be on the order of 5–10% indicating
a metabolically active glutamic acid decarboxylase with
a participating GABA concentration on the order of
0.5 Ìmol/g.
We further noted that the lactate methyl peak was
readily observed in the human brain and appeared to be
easily labeled by 13C label derived from plasma glucose
(fig. 2). The intensity of this peak was estimated relative
to the natural abundance NAA methyl peak at 22.7 ppm
which corresponds to approximately 0.1 Ìmol/g 13C con-
centration. Preliminary estimates of the minimum lactate
pool size were obtained by dividing the 13C lactate signal
intensity by half the fractional enrichment of plasma
glucose. The pool size of lactate was approximately 0.5
Ìmol/g which is comparable to the reported total lactate
of 0.6–1 Ìmol/g in resting human brain [40].
Figure 3 illustrates the time course of the amino acid
C2 resonances together with the NAA C2 peak. Stability
of the NAA C2 signal measured at 54.0 ppm throughout
this 2-hour measurement period is indicated by the open
circles. Additional measurements over extended periods
up to 6 h confirmed the impression that in the normal,
human brain in vivo turnover of NAA may be very low.
When allowing for a very conservatively estimated 100%
increase in NAA signal from 0.1 to 0.2 Ìmol/g over 3 h,
an upper limit for its turnover rate can be estimated at
0.03 Ìmol/g/h. Aspartate, however, labeled readily in all
subjects studied. The plot in figure 3 shows that aspar-
tate labeling leveled approximately 40 min after start of
the infusion. This is consistent with malate-aspartate
shuttle being the mechanism to exchange label with its
partner (oxaloacetate) in the TCA cycle. Glutamate is
likely to be transported by the same mechanism across
A
B
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Fig. 4. Direct 13C-NMR detection of la-
bel accumulation in a 22.5-ml volume
encompassing the human visual cortex.
A shows a stack plot with 3 min time resolu-
tion of the region containing the Glu C4 res-
onance at 34.2 ppm, B shows observation of
less concentrated signals when extending
data accumulation periods to 12 min prein-
fusion (bottom) and to 30 min after infusion
start (top) and C is the plot of the Glu C4
intensity in A.
the mitochondrial membrane as part of the malate-
aspartate shuttle.
A preliminary analysis indicated that labeling of Gln
relative to Glu at the C2 position was 0.39 B 0.10 (mean
B SD, n = 4) which was higher than that at the C3 posi-
tion (0.18 B 0.03, p ! 0.05) and tentatively higher than at
the C4 position (0.26 B 0.09). Gln isotopomers not being
equal to those of Glu imply that pyruvate carboxylase flux
is significant in the resting human brain. The C4 of gluta-
mine labeled somewhat more slowly than the C4 of gluta-
mate, consistent with an earlier report [6]. However,
when plotting the time course of glutamine C2 against glu-
tamate C2 such a delay in labeling was not apparent.
These preliminary observations are also consistent with a
substantial pyruvate carboxylase activity.
The data presented in figures 1 and 2 sampled rather
large volumes in the occipital lobe of the human brain on
the order of 100 ml. To evaluate the potential to extend
these measurements to areas consistently and homoge-
nously activated by focal activation, such as the human
visual cortex, we acquired a time course from a 22.5 ml
(3 ! 3 ! 2.5 cm3) volume centered in the primary visual
cortex. The time course of the Glu C4 can be readily
observed, as shown in figure 4A. Extended periods of sig-
nal accumulation permitted assessment of the labeling of
other metabolites such as Gln and Asp (fig. 4B). The time
course of Glu C4 corresponding to the stack plot in fig-
ure 4A is shown in figure 4C.
Discussion
The present study shows that the time course of label
incorporation in vivo into cerebral glucose can be mea-
sured and that the sensitivity is sufficient to calculate in
vivo fractional enrichment of glucose. Consistent results
were achieved with a high enrichment of approximately
67% using a much simplified infusion protocol, as evi-
denced by figure 1B and table 1. To achieve a high frac-
tional enrichment in the labeled precursor, glucose, in an
economical manner, plasma glucose levels were increased
in this study acutely, but modestly. Such small increases
in plasma glucose are not expected to alter brain glucose
metabolism rates nor transport rate constants over the
time frame of the present study. Intracellular brain glu-
cose is generally assumed not to be a regulatory factor for
cerebral glucose metabolism, which is consistent with a
tissue concentration well above the Km of hexokinase in
human brain at euglycemia and above [30, 31].
The present initial study further demonstrates that
localized observation of 13C label incorporation into all
CHn groups of most major amino acids is possible in the
human brain. In addition to the C4 of Gln, the C3 as well
as the C2 of Gln have been easily resolved from the corre-
sponding resonance of Glu, which represents a significant
extension of previous studies [6, 25], which did not report
such a capability. Labeling of the Asp C2 and C3 reso-
nances was readily observed in the present study (fig. 2) as
well as the three natural abundance CHn peaks of NAA.
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The much improved sensitivity of the present study over
previous reports is attributed mainly to the increased field
strength as was previously documented using natural
abundance 13C-NMR [32]. In the present study, the high-
er magnetic field strength led to the in vivo observation of
the GABA C2 resonance at 35.3 ppm, which may have
been previously masked at lower field strength by overlap
with the downfield part of the 13C-13C doublet at Glu C4.
Finally, we note that label incorporation into lactate,
another low concentration metabolite that is difficult to
measure in the resting normal human brain even with 1H-
NMR spectroscopy [40–42], was readily observed in this
study using 13C-NMR.
From these observations, several implications for the
study of human cerebral neurochemistry can be drawn:
First, the apparent stability of three NAA resonances dur-
ing 13C infusions lasting up to 6 h suggest that in the normal
human brain, the N-acetylaspartate turnover rate is below
0.03 Ìmol/g/h. However, this may be different under
pathologic conditions and remains to be further elucidated.
Second, the GABA resonance was observed at 35.3 ppm
after 1-13C glucose infusion which is consistent with a met-
abolically active pool size of 0.5–1 Ìmol/g in the resting
human visual cortex. The GABA pool size is comparable to
total GABA concentration [43, 44] which suggests a very
active flux through glutamic acid decarboxylase. Third,
from the observation of significant 13C-labeled lactate, we
conclude that in the resting human brain, when oxidative
metabolism is tightly coupled to glycolysis [45], significant
lactate metabolism is present, consistent with measure-
ments of lactate readily crossing the blood-brain barrier
[46]. This observation indicates that the necessary sub-
strate concentration is present to drive lactate produced in
glial cells to the neurons for oxidative metabolism [2]. Fur-
thermore, the labeling of lactate from 1-13C glucose suggests
that plasma glucose is the major source of cerebral lactate,
although it remains to be shown to what extent label incor-
poration occurs indirectly via, e.g., glutamate [3].
Because of the scarcity of in vivo data, few studies have
attempted to model in vivo time courses. Noteworthy
exceptions are the reports by Mason et al. [7] modeling
single-compartment Glu C4/C3 labeling kinetics in hu-
man brain [based on data reported in 6] and including the
modeling of Gln C4 turnover. However, brain metabo-
lism is clearly multicompartmental and extract studies
have recognized this fact [e.g., 5, 12, 24]. Recently, an in
vivo study has included the glial compartment [25] for
modeling Glu C4 and Gln C4 label accumulation. Unfor-
tunately, the model therefore was restricted to the mea-
surement of TCA cycle flux (from Glu C4) and to sepa-
rately calculating the rate of apparent neurotransmission
(denoted in that paper flux from glutamate to glutamine,
Vgln) from Gln C4.
The information content present in our spectra allows
for additional information to be assessed. The informa-
tion that can potentially be modeled based on such in vivo
measurements is illustrated in figure 5. Assuming rapid
lactate transport across cell membranes, the glial and neu-
ronal Lac pools have been lumped into one kinetic pool,
thus allowing for one metabolic rate for glucose consump-
tion to be modeled. In the TCA cycle, modeling can be
extended significantly over previous studies of the brain:
In addition to the capability of modeling Glu and Gln C4,
the respective C3 and C2 resonances can be measured,
thus allowing assessment of VPC and Vx. The simulta-
neous observation of Glu resonances and of Asp suggests
that the Krebs cycle and associated exchange reactions
can be studied in the human brain at a level hitherto not
possible: The mitochondrial exchange rate Vx also de-
scribes the rate of exchange between Asp and oxaloacetate
(OAA) and the measurement of Asp C2 and C3 is
expected to further shed light on Vx. Conversely, to evalu-
ate the use of Asp in assessing TCA cycle flux, the time
course was fitted to the Asp C2 label accumulation curve.
Assuming Asp = 1 Ìmol/g and Vx/VPDH 11 1 yielded for
two studies 0.5*VPDH = 0.37 B 0.08 Ìmol/g/min, which
was consistent with the value previously reported from
Glu C4/C3 analysis under similar assumptions [7]. Fitting
the model to the C4 resonances of Gln and Glu gave
0.5*VPDH = 0.43 B 0.03 Ìmol/g/min and VNT
app = 0.32 B
0.09 Ìmol/g/min for the study shown in figure 3A. The
model further predicts that if metabolic trafficking due to
neurotransmitter release (indicated by glutamate and glu-
tamine exchange and denoted by VNT
app in fig. 5) is very fast
compared to the glial metabolic rates, e.g. VPC, the rate
and extent of labeling of Gln at steady state must be iden-
tical relative to the corresponding Glu position. The
increased label at the C2 of Gln relative to Glu suggests
that pyruvate carboxylase activity may be significant in
the resting human brain, although its contribution ap-
pears to be small. Simulations performed at t = 60 min
suggested relative label in Gln C2 elevated compared to
C3 by approximately 80% is consistent with VPC/VNT
app
F0.25, i.e. 0.08 Ìmol/g/min. This value may appear high;
however, in primary cultures of adult brain and astrocytes
a rate of 1.2–1.8 nmol/mg protein/min was measured
[16]. More studies combined with extensive modeling are
needed and planned to further delineate the accuracy of
our observations. Nevertheless, since pyruvate carboxy-
lase is localized exclusively to glia and its activity can lead
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Fig. 5. Proposed modeling of 13C label-
ing observed in the human brain. Observed
metabolite pools with the corresponding la-
beled position in the molecule indicated by
the subscript are indicated in bold type. All
other metabolites are assumed to be below
0.1 Ìmol/g and are assumed to have a negli-
gible effect on labeling kinetics. Enzymes are
heavily compartmentalized between glial
type cells and neuronal type cells, such as
pyruvate carboxylase, EC 6.4.1.1, whose flux
is indicated by VPC, glutamine synthetase
(EC 6.3.1.2, Vsyn), glutaminase (EC 3.5.1.2,
VNT
app in neurons, Vgase in glia). Glu and Gln
are compartmentalized as well, with Glu
predominantly neuronal and Gln predomi-
nantly glial. The excess carbon skeletons pro-
duced by VPC were assumed to result in Gln
efflux (Vefflux = VPC). The measurement of
ten labeling curves (three each for Glu and
Gln, two for Asp and one each for glucose
and lactate) can be used to determine the fol-
lowing five independent metabolic rates: the
apparent rate of neurotransmission VNT
app, mi-
tochondrial exchange rate Vx, neuronal TCA
cycle rate, denoted VPDH, pyruvate carbox-
ylase, VPC, and the glucose cerebral metabol-
ic rate CMRglc.
to a different label distribution in glutamine than in gluta-
mate, these results underline the potential of localized, in
vivo 13C-NMR to quantitate glial metabolism in vivo,
whose quantitative contribution to total brain energy me-
tabolism remains to be defined in vivo.
The present study was performed on human brain.
Nevertheless, the 13C-NMR localization methods de-
scribed in this paper are extendable to in vivo animal
brain studies, where the unrestricted use of RF power
(SAR) permits uncompromised pulse sequence perfor-
mance. We conclude that the presented methods to study
in vivo cerebral metabolism permit a detailed study of in
vivo neurochemistry and of several biochemical reactions
and pathways. These measurements should be useful in
understanding in vivo brain energy metabolism as well as
metabolic trafficking in the normal brain, brain develop-
ment and pathophysiological states such as neurodegener-
ative diseases, as well as stroke, epilepsy and hepatic
encephalopathy.
Acknowledgements
Supported by NIH grants RR08079 and RR00400, R01NS3556.
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
References
1 Van den Berg C: A model of compartmentation
in mouse brain based on glucose and acetate
metabolism; in Balazs E, Cremer J (eds): Meta-
bolic Compartmentation in the Brain. London,
Macmillan, 1973, pp 137–166.
2 Magistretti P, Pellerin L: Cellular mechanisms
of brain energy metabolism. Relevance to func-
tional brain imaging and to neurodegenerative
disorders. Ann NY Acad Sci 1996;777:380–
387.
3 Hassel B, Sonnewald U, Fonnum F: Glial-neu-
ronal interactions as studied by cerebral metab-
olism of [2-13C]acetate and [1-13C]glucose: An
ex vivo 13C-NMR spectroscopic study. J Neu-
rochem 1995;64:2773–2783.
4 Leo GC, Driscoll BF, Shank RP, Kaufman E:
Analysis of [1-13C]D-glucose metabolism in
cultured astrocytes and neurons using nuclear
magnetic resonance spectroscopy. Dev Neuro-
sci 1993;15:282–288.
5 Lapidot A, Gopher A: Cerebral metabolic com-
partmentation. Estimation of glucose flux via
pyruvate carboxylase/pyruvate dehydrogenase
by 13C-NMR isotopomer analysis of [U-13C]D-
glucose metabolites. J Biol Chem 1994;269:
27198–27208.
6 Gruetter R, Novotny EJ, Boulware SD, Mason
GF, Rothman DL, Prichard JW, Shulman RG:
Localized 13C-NMR spectroscopy of amino
acid labeling from [1-13C]D-glucose in the hu-
man brain. J Neurochem 1994;63:1377–1385.
388 Dev Neurosci 1998;20:380–388 Gruetter/Seaquist/Kim/Ugˇurbil
7 Mason GF, Gruetter R, Rothman DL, Behar
KL, Shulman RG, Novotny EJ: Simultaneous
determination of the rates of the TCA cycle,
glucose utilization, ·-ketoglutarate/glutamate
exchange, and glutamine synthesis in human
brain by NMR. J Cereb Blood Flow Metab
1995;15:12–25.
8 Yu X, Alpert NM, Lewandowski ED: Modeling
enrichment kinetics from dynamic 13C-NMR
spectra: Theoretical analysis and practical con-
siderations. Am J Physiol 1997;41:C2037–
C2048.
9 Shank R, Aprison M: Biochemical aspects of
the neurotransmitter function of glutamate; in
Filer LJ (ed): Glutamic Acid: Advances in Bio-
chemistry and Physiology. New York, Raven
Press, 1979, pp 139–150.
10 Schuldiner S, Shirvan A, Linial M: Vesicular
neurotransmitter transporters: From bacteria
to humans. Physiol Rev 1995;75:369–392.
11 Bachelard H, Badar-Goffer R: NMR spectros-
copy in neurochemistry. J Neurochem 1993;
61:412–429.
12 Cerdan S, Kunnecke B, Seelig J: Cerebral me-
tabolism of [1,2-13C2]acetate as detected by in
vivo and in vitro 13C-NMR. J Biol Chem 1990;
265:12916–12926.
13 Shank RP, Leo GC, Zielke HR: Cerebral meta-
bolic compartmentation as revealed by nuclear
magnetic resonance analysis of D-[1-13C]glu-
cose metabolism. J Neurochem 1993;61:315–
323.
14 Brand A, Richter-Landsberg C, Leibfritz D:
Multinuclear NMR studies on the energy me-
tabolism of glial and neuronal cells. Dev Neu-
rosci 1993;15:289–298.
15 Martinez-Hernandez A, Bell KP, Norenberg
MD: Glutamine synthetase: Glial localization
in brain. Science 1976;195:1356–1358.
16 Yu A, Drejer J, Hertz L, Schousboe A: Pyru-
vate carboxylase activity in primary cultures of
astrocytes and neurons. J Neurochem 1983;41:
1484–1487.
17 Hogstad S, Svenneby G, Torgner IA, Kvamme
E, Hertz L, Schousboe A: Glutaminase in neu-
rons and astrocytes cultured from mouse brain:
Kinetic properties and effects of phosphate,
glutamate, and ammonia. Neurochem Res
1988;13:383–388.
18 Pow DV, Crook DK: Direct immunocyto-
chemical evidence for the transfer of glutamine
from glial cells to neurons – use of specific anti-
bodies directed against the d-stereoisomers of
glutamate and glutamine. Neurosci 1996;70:
295–302.
19 van Zijl PCM, Rothman D: NMR studies of
brain C-13-glucose uptake and metabolism –
Present status. Magn Reson Imaging 1995;13:
1213–1221.
20 Rothman DL, Novotny EJ, Shulman GI,
Howseman AM, Petroff OAC, Mason GF, Nix-
on T, Hanstock CC, Prichard JW, Shulman
RG: 1H-[13C]NMR measurement of [4-13C]glu-
tamate. Proc Natl Acad Sci USA 1992;89:
9603–9606.
21 Pan JLW, Mason GF, Vaughan JT, Chu WJ,
Zhang YT, Hetherington HP: C-13 editing of
glutamate in human brain using J-refocused
coherence transfer spectroscopy at 4.1 T. Magn
Reson Med 1997;37:355–358.
22 Kanamori K, Ross BD, Tropp J: Selective, in
vivo observation of [5–15N]glutamine amide
protons in rat brain by 1H-15N heteronuclear
multiple-quantum-coherence transfer NMR. J
Magn Reson B 1995;107:107–115.
23 Lukkarinen J, Oja JM, Turunen M, Kauppinen
RA: Quantitative determination of glutamate
turnover by 1H-observed, 13C-edited nuclear
magnetic resonance spectroscopy in the cere-
bral cortex ex vivo: Interrelationships with oxy-
gen consumption. Neurochem Int 1997;31:95–
104.
24 Merle M, Martin M, Villegier A, Canioni P:
Mathematical modelling of the citirc acid cy-
cle for the analysis of glutamine isotopo-
mers from cerebellar astrocytes incubated with
[1(-13)C]glucose. Eur J Biochem 1996;239:742–
751.
25 Sibson NR, Dhankhar A, Mason GF, Behar
KL, Rothman DL, Shulman RG: In vivo 13C
NMR measurements of cerebral glutamine
synthesis as evidence for glutamate-glutamine
cycling. Proc Natl Acad Sci USA 1997;94:
2699–2704.
26 Sonnewald U, Therrien G, Butterworth RF:
Portacaval anastomosis results in altered neu-
ron-astrocytic metabolic trafficking of amino
acids: Evidence from 13C-NMR studies. J Neu-
rochem 1996;67:1711–1717.
27 Yudkoff M, Nelson D, Daikhin Y, Erecinska
M: Tricarboxylic acid cycle in rat brain synap-
tosomes. Fluxes and interactions with aspar-
tate aminotransferase and malate/aspartate
shuttle. J Biol Chem 1994;269:27414–27420.
28 McKenna M, Sonnewald U, Huang X, Steven-
son J, Zielke H: Exogeneous glutamate concen-
tration regulates the metabolic fate of gluta-
mate in astrocytes. J Neurochem 1996;66:386–
393.
29 Beckmann N, Turkalj I, Seelig J, Keller U: 13C
NMR for the assessment of human brain glu-
cose metabolism in vivo. Biochemistry 1991;
30:6362–6366.
30 Gruetter R, Novotny EJ, Boulware SD, Roth-
man DL, Mason GF, Shulman GI, Shulman
RG, Tamborlane WV: Direct measurement of
brain glucose concentrations in humans by 13C
NMR spectroscopy. Proc Natl Acad Sci USA
1992;89:1109–1112.
31 Gruetter R, Ugurbil K, Seaquist ER: Steady-
state cerebral glucose concentrations and trans-
port in the human brain. J Neurochem 1998;
70:397–408.
32 Gruetter R, Adriany G, Merkle H, Andersen
PM: Broadband decoupled, 1H localized 13C
MRS of the human brain at 4 Tesla. Magn
Reson Med 1996;36:659–664.
33 Adriany G, Gruetter R: A half volume coil for
efficient proton decoupling in humans at 4 Tes-
la. J Magn Reson 1997;125:178–184.
34 Seaquist ER: Comparison of arterialized ve-
nous sampling from the hand and the foot in
the assessment of in vivo glucose metabolism.
Metabolism 1997;46:1364–1366.
35 Seaquist ER, Pyzdrowski K, Moran A, Teu-
scher AU, Robertson RP: Insulin-mediated
and glucose-mediated glucose uptake following
hemipancreatectomy in healthy human do-
nors. Diabetologia 1994;37:1036–1043.
36 Gruetter R: Automatic, localized in vivo ad-
justment of all first- and second-order shim
coils. Magn Reson Med 1993;29:804–811.
37 Garwood M, Ke Y: Symmetric pulses to induce
arbitrary flip angles with compensation for RF
inhomogeneity and resonance offsets. J Magn
Reson 1991;94:511–525.
38 McKenna MC, Tildon JT, Stevenson JH, Hop-
kins IB: Energy metabolism in cortical synaptic
terminals from weanling and mature rat brain:
Evidence for multiple compartments of tricar-
boxylic acid cycle activity. Dev Neurosci 1994;
16:291–300.
39 Gruetter R, Novotny EJ, Boulware SD, Roth-
man DL, Shulman RG: 1H NMR studies of glu-
cose transport in the human brain. J Cereb
Blood Flow Metab 1996;16:427–438.
40 Prichard J, Rothman D, Novotny E, Petroff O,
Kuwabara T, Avison M, Howseman A, Han-
stock C, Shulman R: Lactate rise detected by
1H NMR in human visual vortex during physi-
ologic stimulation. Proc Natl Acad Sci USA
1991;88:5829–5831.
41 Frahm J, Kruger G, Merboldt KD, Klein-
schmidt A: Dynamic uncoupling and recou-
pling of perfusion and oxidative metabolism
during focal brain activation in man. Magn
Reson Med 1996;35:143–148.
42 Sappey-Marinier D, Calabrese G, Fein G,
Hugg JW, Biggins C, Weiner MW: Effect of
photic stimulation on human visual cortex lac-
tate and phosphates using 1H and 31P magnetic
resonances spectroscopy. J Cereb Blood Flow
Metab 1992;12:584–592.
43 Rothman DL, Petroff OAC, Behar KL, Matt-
son RH: Localized 1H NMR measurements of
GABA levels in human brain in vivo. Proc Natl
Acad Sci USA 1993;90:5662–5666.
44 Mescher M, Merkle H, Kirsch J, Garwood M,
Gruetter R: Simultaneous water suppression
and editing in vivo. NMR Biomed 1998 (in
press).
45 Fox PT, Raichle ME, Mintun MA, Dence C:
Nonoxidative glucose consumption during fo-
cal physiologic neural activity. Science 1988;
241:462–464.
46 Knudsen G, Paulson O, Hertz M: Kinetic anal-
ysis of the human blood-brain barrier transport
of lactate and its influence by hypercapnia. J
Cereb Blood Flow Metab 1991;11:581–586.
